IMMUCELL CORP /DE/

IMMUCELL CORP /DE/ (ICCC) is a publicly listed company on US equity markets.

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

The company reports trailing twelve-month revenue of $6.44M and net income of $1.94M.

Key metrics include a return on equity of 6.7%, a debt-to-equity ratio of 0.51.

Use FINOTAUR to track ICCC's price action, review fundamentals, and stay current with company news — all in one research dashboard.